JP2003516930A - 転移性疾患の治療 - Google Patents
転移性疾患の治療Info
- Publication number
- JP2003516930A JP2003516930A JP2001516518A JP2001516518A JP2003516930A JP 2003516930 A JP2003516930 A JP 2003516930A JP 2001516518 A JP2001516518 A JP 2001516518A JP 2001516518 A JP2001516518 A JP 2001516518A JP 2003516930 A JP2003516930 A JP 2003516930A
- Authority
- JP
- Japan
- Prior art keywords
- epha2
- cells
- antibody
- metastatic
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14925899P | 1999-08-17 | 1999-08-17 | |
| US60/149,258 | 1999-08-17 | ||
| PCT/US2000/022670 WO2001012172A1 (en) | 1999-08-17 | 2000-08-17 | Treatment of metastatic disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007211840A Division JP2007306938A (ja) | 1999-08-17 | 2007-08-15 | 転移性疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003516930A true JP2003516930A (ja) | 2003-05-20 |
| JP2003516930A5 JP2003516930A5 (cg-RX-API-DMAC7.html) | 2008-06-05 |
Family
ID=22529456
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001516518A Pending JP2003516930A (ja) | 1999-08-17 | 2000-08-17 | 転移性疾患の治療 |
| JP2007211840A Pending JP2007306938A (ja) | 1999-08-17 | 2007-08-15 | 転移性疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007211840A Pending JP2007306938A (ja) | 1999-08-17 | 2007-08-15 | 転移性疾患の治療 |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP2289940A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2003516930A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE324877T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU6784400A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2380888A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60027768T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1242060T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2261230T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1242060E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001012172A1 (cg-RX-API-DMAC7.html) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008500021A (ja) * | 2003-11-20 | 2008-01-10 | メディミューン,インコーポレーテッド | EphA2アゴニストモノクローナル抗体およびその使用法 |
| JP2009543575A (ja) * | 2006-07-18 | 2009-12-10 | サノフイ−アベンテイス | 癌治療用対epha2アンタゴニスト抗体 |
| WO2014126160A1 (ja) * | 2013-02-13 | 2014-08-21 | 国立大学法人東京大学 | がんの検査方法及び検査用キット |
| WO2018034332A1 (ja) * | 2016-08-19 | 2018-02-22 | 国立大学法人東京大学 | EphA2 N末端フラグメント抗体 |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| DZ3332A1 (fr) | 2000-03-31 | 2001-10-11 | Purdue Research Foundation | Methode de traitement a l'aide de conjugues ligand-immunogene |
| US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
| NZ537458A (en) * | 2001-01-23 | 2007-02-23 | Primagen Holding B | Means and methods for treatment evaluation |
| EP1225233A3 (en) * | 2001-01-23 | 2003-01-08 | Amsterdam Support Diagnostics B.V. | Means and methods for treatment evaluation |
| EP1298221A1 (en) * | 2001-09-28 | 2003-04-02 | PrimaGen Holding B.V. | Means and methods for treatment evaluation |
| DE60234782D1 (de) * | 2001-09-28 | 2010-01-28 | Purdue Research Foundation | Behandlungsverfahren mit liganden-immunogenkonjugaten |
| AU2003215190A1 (en) * | 2002-02-15 | 2003-09-09 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. |
| EP1519956B1 (en) * | 2002-05-10 | 2011-09-21 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
| EP1575509B1 (en) * | 2002-05-10 | 2011-10-26 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
| EP1505999A4 (en) | 2002-05-23 | 2009-07-08 | Purdue Research Foundation | LOW-MOLECULAR PROTEIN-TYROSINE PHOSPHATASE (LMW-PTP) AS DIAGNOSTIC AND THERAPEUTIC TARGET |
| AU2004210463B2 (en) * | 2003-02-07 | 2009-07-16 | Ludwig Institute For Cancer Research Limited | Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis |
| AU2003900541A0 (en) * | 2003-02-07 | 2003-02-20 | Ludwig Institute For Cancer Research | Modulation of cell adhesion and tumour cell metastasis |
| EP1617864A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING |
| EP1618184A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION |
| CA2525929A1 (en) | 2003-05-13 | 2004-11-25 | Chiron Corporation | Methods of modulating metastasis and skeletal related events resulting from metastases |
| WO2005016381A2 (en) * | 2003-07-21 | 2005-02-24 | Medimmune, Inc. | Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah |
| PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| AU2005277641A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| BRPI0607450A2 (pt) | 2005-02-04 | 2009-09-01 | Raven Biotechnologies Inc | anticorpos que se ligam a epha2 e métodos para sua utilização |
| WO2007092299A2 (en) | 2006-02-03 | 2007-08-16 | Purdue Research Foundation | Targeted conjugates and radiation |
| AU2007342333B2 (en) | 2006-09-12 | 2013-02-28 | Alphavax, Inc. | Alphavirus replicon particles encoding IL- 12 as immunological adjuvants |
| US20090022760A1 (en) | 2006-09-12 | 2009-01-22 | Alphavax | Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants |
| US20090047255A1 (en) | 2006-11-03 | 2009-02-19 | Alphavax, Inc. | Alphavirus and Alphavirus Replicon Particle Formulations and Methods |
| WO2009028639A1 (ja) * | 2007-08-30 | 2009-03-05 | Daiichi Sankyo Company, Limited | 抗epha2抗体 |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| US20210268098A1 (en) | 2018-08-03 | 2021-09-02 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07132084A (ja) * | 1992-11-24 | 1995-05-23 | Bristol Myers Squibb Co | Her4ヒト受容体チロシンキナーゼ |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993003741A1 (en) | 1991-08-22 | 1993-03-04 | Becton, Dickinson & Company | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
| US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| ES2242437T3 (es) * | 1998-11-20 | 2005-11-01 | Genentech, Inc. | Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares. |
-
2000
- 2000-08-17 EP EP10010861A patent/EP2289940A3/en not_active Withdrawn
- 2000-08-17 ES ES00955687T patent/ES2261230T3/es not_active Expired - Lifetime
- 2000-08-17 AU AU67844/00A patent/AU6784400A/en not_active Abandoned
- 2000-08-17 DE DE60027768T patent/DE60027768T2/de not_active Revoked
- 2000-08-17 WO PCT/US2000/022670 patent/WO2001012172A1/en not_active Ceased
- 2000-08-17 CA CA002380888A patent/CA2380888A1/en not_active Abandoned
- 2000-08-17 JP JP2001516518A patent/JP2003516930A/ja active Pending
- 2000-08-17 DK DK00955687T patent/DK1242060T3/da active
- 2000-08-17 AT AT00955687T patent/ATE324877T1/de not_active IP Right Cessation
- 2000-08-17 EP EP00955687A patent/EP1242060B1/en not_active Revoked
- 2000-08-17 PT PT00955687T patent/PT1242060E/pt unknown
-
2007
- 2007-08-15 JP JP2007211840A patent/JP2007306938A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07132084A (ja) * | 1992-11-24 | 1995-05-23 | Bristol Myers Squibb Co | Her4ヒト受容体チロシンキナーゼ |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008500021A (ja) * | 2003-11-20 | 2008-01-10 | メディミューン,インコーポレーテッド | EphA2アゴニストモノクローナル抗体およびその使用法 |
| JP4860477B2 (ja) * | 2003-11-20 | 2012-01-25 | メディミューン,エルエルシー | EphA2アゴニストモノクローナル抗体およびその使用法 |
| JP2009543575A (ja) * | 2006-07-18 | 2009-12-10 | サノフイ−アベンテイス | 癌治療用対epha2アンタゴニスト抗体 |
| WO2014126160A1 (ja) * | 2013-02-13 | 2014-08-21 | 国立大学法人東京大学 | がんの検査方法及び検査用キット |
| JP2014178301A (ja) * | 2013-02-13 | 2014-09-25 | Univ Of Tokyo | がんの検査方法及び検査用キット |
| WO2018034332A1 (ja) * | 2016-08-19 | 2018-02-22 | 国立大学法人東京大学 | EphA2 N末端フラグメント抗体 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK1242060T3 (da) | 2006-08-21 |
| JP2007306938A (ja) | 2007-11-29 |
| PT1242060E (pt) | 2006-08-31 |
| EP1242060A1 (en) | 2002-09-25 |
| WO2001012172B1 (en) | 2001-08-16 |
| WO2001012172A1 (en) | 2001-02-22 |
| DE60027768D1 (de) | 2006-06-08 |
| EP1242060B1 (en) | 2006-05-03 |
| ATE324877T1 (de) | 2006-06-15 |
| EP2289940A3 (en) | 2011-09-21 |
| AU6784400A (en) | 2001-03-13 |
| CA2380888A1 (en) | 2001-02-22 |
| DE60027768T2 (de) | 2007-04-05 |
| EP1242060A4 (en) | 2003-09-24 |
| ES2261230T3 (es) | 2006-11-16 |
| EP2289940A2 (en) | 2011-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8591887B2 (en) | EPHA2 as a therapeutic target for cancer | |
| EP1242060B1 (en) | Treatment of metastatic disease | |
| JP7316862B2 (ja) | 小細胞肺癌に対する標的療法 | |
| JP4726777B2 (ja) | 癌疾患修飾抗体 | |
| AU2011200789B2 (en) | Cytotoxicity mediation of cells evidencing surface expression of CD44 | |
| JP5367776B2 (ja) | Cd44表面発現を示している細胞の結合検定法及び単離法 | |
| US20030082188A1 (en) | Treatment of prostate cancer by inhibitors of NCAM2 | |
| JP2012031183A (ja) | Cd44の表面発現を証明する細胞の細胞毒性媒介 | |
| CN101107267A (zh) | 对表面表达有mcsp的细胞的细胞毒性的介导 | |
| JP2008545615A (ja) | Cd63の表面発現を証明する細胞の細胞毒性仲介 | |
| US20240174762A1 (en) | Methods, compositions and uses for targeting sema7a in the diagnosis and treatment of health conditions | |
| AU2006202023B2 (en) | Treatment of metastatic disease | |
| EP1695702A2 (en) | Treatment of metastatic disease | |
| US20040048817A1 (en) | Methods of immunotherapy and diagnosis | |
| CN113773389B (zh) | 鼠抗人胸苷激酶1单克隆抗体及其制药用途 | |
| WO2012133994A1 (ko) | Pauf 및 그의 결합 파트너를 상호작용을 이용한 암 치료제의 스크리닝 방법 | |
| US20040022786A1 (en) | Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins | |
| HK1121376A (en) | Cancerous disease modifying antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20040524 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040524 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20040524 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070815 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070815 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080415 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100601 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100805 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100930 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101007 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101029 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101207 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110606 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110606 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111206 |